Search research articles
Contact Us
Filters
Showing results (181-190 of 272) with videos related to
Page
of 28
Sort By:
The Journal of Pathology. Clinical Research
|
January 16, 2026
Alcian blue-positive stromal phenotype in basal cell carcinoma is associated with progression on first-line hedgehog inhibitors
Viola K DeTemple, Rudolf Stadler, Sabine Bredemeier, et al.
Nature Communications
|
March 11, 2025
Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer
Esra Güç, Agatha Treveil, Emma Leach, et al.
The British Journal of Dermatology
|
July 27, 2025
Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma - clinical activity and safety results from AliCe, a single-arm, multicentre phase 2 DeCOG trial
Jürgen C Becker, Anja H Gesierich, Ulrike Leiter, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 6, 2021
Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response
Florentia Dimitriou, Anne Zaremba, Clara Allayous, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 14, 2025
Clinical course of Merkel cell carcinoma: A DeCOG multicenter study of 1049 patients
Georg C Lodde, Ulrike Leiter, Anja Gesierich, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 3, 2021
Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group
Imke Grimmelmann, Michael Momma, Lisa Zimmer, et al.
Future Oncology (London, England)
|
September 17, 2020
Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab
Murtuza Bharmal, Sandra Nolte, Céleste Lebbé, et al.
Journal for Immunotherapy of Cancer
|
June 6, 2024
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma
Joseph J Sacco, Richard D Carvajal, Marcus O Butler, et al.
Frontiers in Oncology
|
June 10, 2021
Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study
Katharina C Kähler, Ralf Gutzmer, Friedegrund Meier, et al.
Lancet (London, England)
|
July 14, 2023
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial
Jürgen C Becker, Selma Ugurel, Ulrike Leiter, et al.
Page
of 28
Search research articles
Search
Showing results (181-190 of 272) with videos related to
Sort By:
Page
of 28
The Journal of Pathology. Clinical Research
|
January 16, 2026
Alcian blue-positive stromal phenotype in basal cell carcinoma is associated with progression on first-line hedgehog inhibitors
Viola K DeTemple, Rudolf Stadler, Sabine Bredemeier, et al.
Nature Communications
|
March 11, 2025
Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer
Esra Güç, Agatha Treveil, Emma Leach, et al.
The British Journal of Dermatology
|
July 27, 2025
Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma - clinical activity and safety results from AliCe, a single-arm, multicentre phase 2 DeCOG trial
Jürgen C Becker, Anja H Gesierich, Ulrike Leiter, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 6, 2021
Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response
Florentia Dimitriou, Anne Zaremba, Clara Allayous, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 14, 2025
Clinical course of Merkel cell carcinoma: A DeCOG multicenter study of 1049 patients
Georg C Lodde, Ulrike Leiter, Anja Gesierich, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 3, 2021
Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group
Imke Grimmelmann, Michael Momma, Lisa Zimmer, et al.
Future Oncology (London, England)
|
September 17, 2020
Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab
Murtuza Bharmal, Sandra Nolte, Céleste Lebbé, et al.
Journal for Immunotherapy of Cancer
|
June 6, 2024
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma
Joseph J Sacco, Richard D Carvajal, Marcus O Butler, et al.
Frontiers in Oncology
|
June 10, 2021
Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study
Katharina C Kähler, Ralf Gutzmer, Friedegrund Meier, et al.
Lancet (London, England)
|
July 14, 2023
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial
Jürgen C Becker, Selma Ugurel, Ulrike Leiter, et al.
Page
of 28